Loading...
Glaukos Corp (GKOS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company shows strong growth potential, supported by bullish technical indicators, positive analyst sentiment, and significant hedge fund buying. Although the company is not yet profitable, its revenue growth and expanding gross margins indicate a promising trajectory. The SwingMax signal further supports a buy decision.
The stock is showing bullish technical indicators: the MACD is positively expanding, RSI is neutral but leaning bullish, and moving averages (SMA_5 > SMA_20 > SMA_200) confirm an uptrend. The current price of $121.35 is near the R1 resistance level of $121.832, suggesting potential for further upside.

Analysts have consistently raised price targets, with the highest target at $160, indicating strong confidence in the company's growth potential.
Hedge fund buying has surged by 318.02% in the last quarter, signaling institutional confidence.
FDA approval for repeat dosing of iDose expands its market potential.
Revenue growth of 35.66% YoY and gross margin improvement to 77.8% highlight strong operational performance.
The company is still unprofitable, with a net income of -$133.66M in Q4
The stock has a 40% chance of a slight decline (-2.65%) in the next week, though this is outweighed by its long-term growth prospects.
In Q4 2025, revenue increased by 35.66% YoY to $143.12M. Net income improved significantly by 298.03% YoY to -$133.66M, and EPS increased by 286.67% YoY to -2.32. Gross margin rose to 77.8%, up 6.78% YoY, indicating operational efficiency.
Analysts are overwhelmingly positive, with multiple Buy and Overweight ratings. Price targets have been raised consistently, with the highest target at $160. Analysts highlight the company's strong growth trajectory, particularly with iDose and Epioxa, which are expected to drive significant revenue acceleration in the coming years.